Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Beyfortus is recommended for every healthy newborn, and for some practices, that’s a lot of babies to cover. “You’re easily getting into the hundreds of thousands of dollars for a medium- ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe, and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.

The list price for Sanofi’s antibody product, Beyfortus, is $495 a dose; babies would receive one dose. The list price for the maternal vaccine is $295 a dose, which is hefty for a vaccine.

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.